Navigation Links
Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
Date:11/21/2012

SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- Trovagene, Inc.  (NASDAQ: TROV), a transrenal molecular diagnostic company, today announced the closing of a private placement consisting of 940,000 units at a purchase price of $4.00 per unit, with each unit consisting of one share of unregistered common stock and one warrant to purchase one share of common stock. The gross proceeds to Trovagene from this offering are approximately $3.76 million. The warrants are exercisable for five years from the date of closing at an exercise price of $5.32 per share.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

Trovagene intends to use the net proceeds from this private placement offering to fund its research and development activities, and for working capital and other general corporate purposes.

"This private placement is well timed to provide Trovagene with sufficient capital to facilitate the availability of transrenal oncogene mutation testing to clinicians through our diagnostic laboratory," stated Antonius Schuh, Ph.D., chief executive officer of Trovagene.  "The Company now has cash in excess of $10 million, which we expect will be sufficient to fund our operations well into 2014."

This announcement is neither an offer to sell nor a solicitation of an offer to buy any securities of the Company. The securities offered and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration under the Securities Act and applicable state securities laws.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detec
'/>"/>

SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dr. Paul Billings joins Trovagenes Scientific Advisory Board
2. Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
3. Trovagene and Strand Life Sciences Agree to Validate and Commercialize Urine-Based HPV Test in India and South Asia
4. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
5. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
6. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
7. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
8. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
9. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
10. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
11. Vasomedical Announces Financial Results for the Third Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Investigation Report on China,s Ranibizumab Market, ... by Novartis, ranibizumab was approved by CFDA to treat ... only Lucentis, a product of Novartis, is available in ... first self- developed drug for the treatment of wet ...
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ... it has completed the acquisition of leading OTC brands ... €200 million. The transaction is a clear demonstration of ... Company,s leading European distribution network spanning 36 countries.  ... C. Papa commented, "We are excited to complete ...
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
(Date:8/30/2015)... ... , ... Natural Rest contains a unique mixture of vitamins and herbs that ... help to improve mood disorders and anxiety. Like all other Creative Medical Health products, ... of regenerative medicine conducted by Dr. Amit Patel of the University of Utah, one ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Executive Vice President Jeff Fernandez will lead the expansion of global ... of cosmeceutical and skin care experience having spent the last 25 years working ...
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, LLC, ... treatment of prostate cancer, has announced the roll-out of its newest technology – ... in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at the ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, ... Applied Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and ... and lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2
... validity of Purdue patents; Receives limited license rights ... ST. LOUIS, June 9 KV Pharmaceutical Company (NYSE: ... it has entered into a settlement agreement with Purdue Pharma ... lawsuit between the two companies. Under the terms of ...
... early in the course of disease is the best approach ... acute myeloid leukemia (AML), according to a new analysis of ... published in the June 10 issue of the Journal ... Cancer Institute and other institutions, provide new guidelines for treatment ...
... , WASHINGTON, June 9 The "Blue Dog Coalition," a ... oppose a strong public option to for-profit health insurers, took ... insurance and drug industries according to Consumer Watchdog. , ... Landrieu (D-LA) now opposes the public option. Landrieu received ...
... expert says, , TUESDAY, June 9 (HealthDay News) -- ... women as their pregnancy progresses, a new Brazilian study ... to 80 percent of moms-to-be suffering heartburn, stomach pain ... worsen over time, and women who avoid taking medicine ...
... PEMBROKE, Bermuda, June 9 Allied World Assurance,Company (U.S.) ... Ltd (NYSE: AWH ), today announced an ... in the United States. The,complimentary service, called "Strategic Response(SM)," ... resources in the,event of a catastrophe. , ...
... New Dialysis Patients Making a Difference in Cutting Patient Mortality ... (NYSE: DVA ), a leading provider of kidney ... today commended Kidney Care Partners for launching the Performance Excellence ... Partners - a coalition of patient advocates, dialysis professionals, care ...
Cached Medicine News:Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 2Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 3Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 4Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 5Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 6Health News:Study IDs benefit of donor SCT for adults with acute myeloid leukemia 2Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 2Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 3Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 4Health News: Acupuncture May Relieve Heartburn In Pregnancy 2Health News: Acupuncture May Relieve Heartburn In Pregnancy 3Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 3Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 2Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 3
Angled shafts with 12 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Right. Most popular size or model....
Angled 13.5 mm adjustable blades. Teeth in lower jaws fit into holes in upper jaws. Grooves in lower jaw for passage of suture needles. Round knurled handle with polished finish....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Delicate # 4...
Medicine Products: